[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-lymphoid-leukemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-lymphoid-leukemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100646575","reassessment-of-the-risk-of-hemolytic-syndrome-in-patients-with-chronic-lymphocytic-leukemia-treated-with-a-regimen-containing-venetoclax-100646575",false,"NCT07691047","Reassessment of the Risk of Hemolytic Syndrome in Patients With Chronic Lymphocytic Leukemia Treated With a Regimen Containing Venetoclax","ELYSA","Inclusion Criteria:\n\n* Patients with chronic lymphocytic leukemia\u002Flymphocytic lymphoma\n* Meeting the treatment criteria according to iwCLL 2018\n* Eligible for treatment with venetoclax in combination with a Bruton's tyrosine kinase inhibitor (ibrutinib, other approved generations) or obinutuzumab\n* First-line treatment or relapse\n\nExclusion Criteria:\n\n* Patients with meningeal and\u002For cerebral involvement\n* Patients with an active, uncontrolled infection\n* Patients scheduled to receive venetoclax monotherapy or rituximab-venetoclax according to the MURANO study regimen (Murano regimen: venetoclax is administered before rituximab)\n* Contraindications to contrast-enhanced CT scanning (severe renal insufficiency, documented allergy to contrast agents).\n* Pregnancy or breastfeeding\n* Individuals deprived of their liberty, under legal guardianship, or under conservatorship\n* Dementia, mental impairment, or psychiatric disorder that could compromise the patient's ability to provide informed consent and\u002For to adhere to the protocol and follow-up requirements of the trial","ALL","18 Years",{"count":19,"type":20},130,"ESTIMATED","INTERVENTIONAL",[23],"NA","Chronic lymphocytic leukemia is a malignant blood disorder characterized by the proliferation of abnormal B lymphocytes in the blood, lymph nodes, and bone marrow. It generally occurs after age 70 and is the fourth most common blood cancer in France, following multiple myeloma, diffuse large B-cell lymphoma, and myelodysplastic syndromes.\n\nTreatments have advanced since 2015 with the introduction of immunotherapy and targeted therapies. The BCL2 inhibitor (venetoclax) is one of these innovative treatments. It is recommended as first-line therapy and for relapse in combination with anti-CD20 monoclonal antibodies and Bruton's tyrosine kinase inhibitors. Early studies showed that initial administration of venetoclax as monotherapy could lead to lysis syndrome as early as the first few days of treatment. This risk was correlated with the venetoclax dose and tumor burden. Prevention guidelines were subsequently proposed to guide management. This risk is therefore assessed before treatment begins (low, moderate, high), based on lymph node size and circulating lymphocyte count.\n\nFor patients at moderate and high risk, a treatment strategy is recommended that includes hyperhydration and uric acid-lowering agents, which may require hospitalization in some cases. The introduction of combination therapies has improved the depth and duration of response (obinutuzumab + venetoclax and ibrutinib + venetoclax). Venetoclax is added after the initiation of partner agents (22 days after obinutuzumab and 3 cycles after ibrutinib). This initial phase of treatment may reduce the risk of hemolytic syndrome. We propose here to reassess the risk of hemolytic syndrome before starting venetoclax in order to simplify management.",[26],"Chronic Lymphoid Leukemia",[28,29,30],"chronic lymphoid leukemia","venetoclax","lysis syndrome","NOT_YET_RECRUITING","2026-07-06",{"date":34,"type":35},"2026-07-08","ACTUAL",{"date":37,"type":20},"2026-07-31",{"date":39,"type":20},"2029-09-30",{"name":41,"class":42},"Private Hospital of Confluent, France","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":67,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100351175","phase-2-allogeneic-hematopoietic-cell-transplantation-from-hla-matched-donor-after-flu-mel-ptcy-versus-flu-mel-atg-reduced-intensity-conditioning-100351175","NCT03852407","Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning","Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning: a Phase II Randomized Study From the Belgian Hematology Society (BHS)","HLA","Inclusion Criteria:\n\nPatients V.1.1. Diseases\n\nHematological malignancies confirmed histologically:\n\n* AML in morphological CR or not in morphological CR but not rapidly progressing (i.e. no need to give treatments such as hydroxyurea to maintain WBC count \\\u003C 10 000 x109\u002FmL);\n* MDS;\n* CML in CP or AP;\n* MPD not in blast crisis,\n* MDS\u002FMPD overlap,\n* ALL in CR;\n* Multiple myeloma;\n* CLL;\n* Non-Hodgkin's lymphoma (aggressive NHL should have chemosensitive disease);\n* Hodgkin's disease with chemosensitive disease or responding to checkpoint inhibitors.\n\n  \\* Clinical situations\n\n  • Theoretical indication for a standard allo-transplant, but not feasible because:\n* Age \\> 50 yrs;\n* Unacceptable end organ performance;\n* The physician's decision;\n* The patient's decision\n\n  * Underlying 'lower risk' disease, for which Reduced Intensity Conditioning is preferred (eg CLL, MCL)\n\n    \\* Other inclusion criteria\n  * Male or female; fertile patients must use a reliable contraception method;\n  * Age 18-75 yrs (children of any age are not allowed in the protocol);\n  * Informed consent given by patient or his\u002Fher guardian if indicated.\n\nDonors\n\n* Male or female;\n* Any age;\n* Human Leukocyte Antigen (HLA)-identical sibling donor or 10 of 10 (HLA-A, -B, -C, -DRB1, and -DQB1) HLA allele matched unrelated donor;\n* Weight \\> 15 Kg (because of leukapheresis);\n* Fulfills criteria for allogeneic Peripheral Blood Stem Cell (PBSC) donation according to standard procedures;\n* Informed consent given by donor or his\u002Fher guardian if indicated, as per donor center standard procedures.\n\nExclusion Criteria:\n\nPatients\n\n* Any condition not fulfilling inclusion criteria;\n* Human Immunodeficiency Virus positive;\n* Non-hematological malignancy(ies) (except non-melanoma skin cancer) active \\\u003C 3 years before Hematopoietic Cell Transplantation (HCT).\n* Life expectancy severely limited by disease other than malignancy;\n* Central Nervous System involvement with disease refractory to intrathecal chemotherapy.\n* Terminal organ failure, except for renal failure (dialysis acceptable)\n\n  1. Cardiac: Symptomatic coronary artery disease; ejection fraction \\\u003C40%; uncontrolled arrhythmia, uncontrolled hypertension;\n  2. Pulmonary: Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)\\\u003C 40% and\u002For receiving supplementary continuous oxygen, Forced Expiratory Volume in 1 Second (FEV1)\\\u003C 40%;\n  3. Hepatic: Fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, uncorrectable hepatic synthetic dysfunction evinced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal liver abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin \\>3 mg\u002FdL, and symptomatic biliary disease;\n* Uncontrolled infection;\n* Karnofsky Performance Score \\\u003C70%;\n* Patient is a fertile man or woman who is unwilling to use contraceptive techniques during and for 12 months following treatment;\n* Patient is a female who is pregnant or breastfeeding;\n* Any condition precluding the use of melphalan or Thymoglobulin;\n\nDonors\n\n* Any condition not fulfilling inclusion criteria;\n* Unable to undergo leukapheresis because of poor vein access or other reasons.","75 Years",{"count":53,"type":20},114,[55],"PHASE2","The present project aims at comparing two conditioning regimens (FM-PTCy vs FM-ATG). The hypothesis is that one or the two regimens will lead to a 2-year cGRFS rate improvement from 30% (the cGRFS rate with FM without ATG\u002FPTCy) to 45% (Pick-a-winner phase 2 randomized study).",[58,59,60,61,62,63,64,26,65,66],"Acute Myeloid Leukemia in Remission","Myelodysplastic Syndromes","Chronic Myeloid Leukemia in Remission","Myeloproliferative Syndrome","Myeloproliferative Disorder","Acute Lymphoid Leukemia in Remission","Multiple Myeloma","Non Hodgkin Lymphoma","Hodgkin Lymphoma",[68,69,70,71,72,73,74,75,76,77,78],"hematological malignancies","Graft versus host disease","GVHD","Progression free survival","Allogeneic hematopoeitic cell transplantation","HLA-matched donor","reduced intensity conditioning","Overall survival","ATG PK","Immunosuppressive regimen","Prophylaxis","RECRUITING","2022-10-11",{"date":82,"type":35},"2022-10-12",{"date":84,"type":35},"2019-02-04",{"date":86,"type":20},"2038-11-01",{"name":88,"class":42},"University of Liege",10]